HER2-targeting immune cells for metastatic breast and prostate cancer
Part of Cancer, Kidney & urinary, Skin clinical trials.
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have metastatic breast cancer or metastatic prostate cancer that has worsened after at least two prior treatments.
- Your cancer is HER2 positive or negative (specific types allowed).
- You have adequate organ function, such as normal blood cell counts and liver/kidney function.
- You are able to perform daily activities with minimal help (ECOG 0 or 1).
- You do not have serious heart disease, active infections, or autoimmune conditions requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests a new combination of targeted therapies (inetetamab plus rapamycin) with chemotherapy for HER2-positive breast cancer that has spread or come back and has a specific genetic change (PAM pathway mutation). It aims to see if this combination can work better than current treatments for people whose cancer has progressed after trastuzumab.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.